Month: June 2021

Exhibit 1 – Compilation map and 2021 drill planExhibit 1 – Compilation map and 2021 drill planExhibit 2 – Table of Diamond Drill ResultsExhibit 2 – Table of Diamond Drill ResultsExhibit 3 – 2018 and 2021 MAG-VLF Survey Area, Lingman Lake propertyExhibit 3 – 2018 and 2021 MAG-VLF Survey Area, Lingman Lake propertyTORONTO, June 07, 2021 (GLOBE NEWSWIRE) — Signature Resources Ltd. (TSXV: SGU, OTCQB: SGGTF, FSE 3S3) (“Signature” or the “Company”) is pleased to announce the first three diamond drill holes (515 metres) of its ongoing 15 diamond drill hole (3,260 metres) winter-spring drill campaign at its 100% owned Lingman Lake Gold Project (“Project”). Drilling was designed to expand the known envelope of mineralization on the western side of the diabase dike...

NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the Treatment of COVID-19 SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the National Institutes of Health (NIH) has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-19. According to a study of cell cultures conducted by NIH researchers, Tempol demonstrated an ability to limit SARS-CoV-2 infection by impairing the activity of a viral enzyme known as RNA replicase. The NIH researchers also found that Tempol “doses used in their antiviral studies could be likely achieved in tissues that are the primary targets for the virus.”1 The June...

— $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to begin in the coming weeks — LEXINGTON, Mass., June 07, 2021 (GLOBE NEWSWIRE) —  Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced it has achieved a manufacturing milestone under the collaboration with Sanofi Pasteur related to its influenza mRNA vaccine program. Translate Bio will receive a $50 million payment from Sanofi Pasteur for the successful manufacture, release, and delivery of clinical drug product to supply Sanofi Pasteur’s Phase 1 influenza...

As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success Newly Disclosed Patient Level Data Demonstrates a 44% Best Overall Response for the HEPZATO Arm Versus 17% for the Best Alternative Care Arm Company Q&A Webinar Today at 8:30am ET NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an oral presentation of positive preliminary efficacy results from its FOCUS Phase III trial of HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma (mOM) at the American Society of Clinical Oncology (ASCO) Annual...

TORONTO, June 07, 2021 (GLOBE NEWSWIRE) — Digihost Technology Inc. (“Digihost” or the “Company”) (TSXV: DGHI; OTCQB: HSSHF) is pleased to announce the launch of its new DigiGreen Initiative, an industry leading plan to reduce the Company’s already low carbon footprint. In addition to achieving technological and economic excellence, since inception, the Company has focused on being a good corporate citizen and operating its business in an environmentally and socially responsible way. As part of this mandate, the Company located its cryptocurrency mining farm in Upstate New York to take advantage of the low carbon emission energy profile of that area. The Company believes that more can be done to further reduce its carbon footprint, while maintaining its industry leading efficient cryptocurrency mining operations, and is therefore...

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting DUBLIN, Ireland, and Boston MA, June 7, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the U.S. Food and Drug Administration (“FDA”) has confirmed that Amryt’s New Drug Application (“NDA”) for Oleogel-S10 for the treatment of Epidermolysis Bullosa (“EB”) will not require an Advisory Committee meeting.   Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. About AmrytAmryt is a global commercial-stage biopharmaceutical company...

MONTREAL, June 07, 2021 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company”), Canada’s leading organic energy drink brand, will report its financial results for the second quarter ended April 30, 2021, after market close on Monday, June 14, 2021. Management will hold a conference call to discuss its financial results the same day at 5:30 p.m. ET. The conference call will include a Q&A period open exclusively to financial analysts who are invited to participate by using the dial-in number provided below. Other interested parties are invited to participate in the call on a listen-only basis and are encouraged to do so via live audio webcast, which will be available on GURU’s website. Second quarter 2021 conference call details:Monday, June 14, 2021, at 5:30 p.m. ET Via webcast at https://edge.media-server.com/mmc/p/kq6sd3b4 Via...

TORONTO, June 07, 2021 (GLOBE NEWSWIRE) — Class 1 Nickel and Technologies Ltd. (CSE: NICO) (OTCQB: NICLF) (“Class 1 Nickel” or the “Company”) is pleased to announce that it has closed its previously announced brokered private placement (the “Offering”) led by Echelon Capital Markets (“Echelon”), as sole agent and bookrunner. Pursuant to the Offering, the Company issued 3,030,000 units to residents of Quebec at a price of $0.65 per Unit and 3,403,334 units to residents in Canada at a price of $0.60 per Unit, resulting in a total of 6,433,334 units (each a “Unit”) issued for total gross proceeds of $4,011,500. Each Unit is comprised of one common share in the capital of the Company (a “Unit Share”), and one common share purchase warrant (a “Warrant”). Each Warrant is exercisable to purchase one common share in the capital of the...

– Preliminary Q2 Results Show Strong Continued Growth and Market Resilience– Reschedule Being Driven by Finalization of Accounting for SPAC Warrants DENVER, June 07, 2021 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (the “Company” or “CPH”), a leading provider of concrete pumping and waste management services in the U.S. and U.K., is providing preliminary financial results for its second quarter of fiscal year 2021 ended April 30, 2021 and has rescheduled its second quarter fiscal 2021 earnings call to June 14, 2021. Preliminary Second Quarter Fiscal Year 2021 Summary vs. Second Quarter of Fiscal Year 2020 (where applicable)Revenue increased 4% to $76.9 million compared to $74.0 million. Gross margin increased 30 basis points to 43.3% compared to 43.0%. Adjusted EBITDA1 increased 7% to $25.0 million...